Patients with asthma and T2 diabetes using SGLT2 inhibitors have a significantly decreased mortality risk within 30 days of an asthma exacerbation.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.

I am a 68-year-old woman who is in relatively good health. My primary exercise is walking my dogs anywhere from 2-5 miles per day. I have two ...

Q: I’m slated to retire next year, and it scares me to death — well, I hope not death, exactly, but I’m not sure what to do ...

Cardiorenal metabolic (CKM) disorders represent a complex and interconnected cluster of conditions—including chronic kidney ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

aDepartment of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Denmark bThe Copenhagen General Population Study, Copenhagen University Hospital - Herlev and Gentofte, ...

Eli Lilly announces positive results from phase 3 ACHIEVE-2 & ACHIEVE-5 trials of orforglipron versus dapagliflozin in adults with type 2 diabetes: Indianapolis Thursday, October ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...